SCHEMBL6326087

SCHEMBL6326087

Cc1ccc(-c2noc(CCC(=O)NCCCNc3n[nH]c(=O)c4ccccc34)n2)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 6/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ LMNA P02545 5/20 0.48
▸ HTT P42858 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ USP2 O75604 3/20 0.48
▸ TP53 P04637 1/20 0.48
▸ HPGD P15428 3/20 0.47
▸ MAPK1 P28482 1/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ GAA P10253 3/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2D6 P10635 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ MAPT P10636 3/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324738 0.91 HPGD (0.47) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6323594 0.89 TSHR (0.51) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6325574 0.89 TSHR (0.58) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6325780 0.88 HPGD (0.47) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6324654 0.88 TSHR (0.60) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6331242 0.88 HPGD (0.48) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6327917 0.87 HPGD (0.47) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6333112 0.87 TSHR (0.51) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6327228 0.87 TSHR (0.58) TSHRSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL6332651 0.87 ALDH1A1 (0.51) TSHRSMN1; SMN2LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 — — EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 — — US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 — — EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 — — US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 TSHR 4656/4885SMN1; SMN2 3494/4885LMNA 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback